Comparing Pain from Cabotegravir and Rilpivirine Injections in Adults with HIV-1
Testing Injection Site and Virtual Reality Headset Use
Led by Centre Hospitalier Régional d'Orléans · Updated on 2025-12-30
120
Participants Needed
5
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the pain caused by injectable antiretroviral ARV treatments Cabotegravir and Rilpivirine affects patients with HIV-1. This study compares pain intensity based on the injection siteeither dorsogluteal or ventroglutealand whether patients wear a virtual reality headset during the injection. The goal is to understand how these factors influence pain and tolerance in HIV-1 patients who are either new to or already receiving these injections.
Participants will receive four injections in different sequences dorsogluteal injection without a headset, ventrogluteal injection without a headset, dorsogluteal injection with a virtual reality headset, and ventrogluteal injection with a headset. Each participant experiences all four procedures in a randomized order. The study includes standard care visits for injections, pain assessment, and monitoring over several months.
Throughout the study, patients will attend five visits including an inclusion visit, multiple follow-ups, and an end-of-study visit. Nurses will examine injection sites and collect information on any pain and side effects. Patients will rate their pain on a numerical scale immediately after injection, several hours later, and daily for seven days. They will also keep a log to track pain and complete satisfaction questionnaires. Researchers will monitor pain intensity, treatment tolerance, and patient preferences over approximately seven to eight months.
CONDITIONS
Brief Title
Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset
Research Team
D
Daniela PIRES ROTEIA
F
Fanny LOUAT
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patient virologically controlled (viral load less than 50 copies/ml)
Patient scheduled to receive cabotegravir and rilpivirine treatment or currently on injectable cabotegravir and rilpivirine prescribed by their doctor
You will not qualify if you...
Patient on another injectable antiretroviral treatment
Patient participating in another clinical trial with medication
Patient with epilepsy
Patient on antidepressant treatment
Patient with psychiatric or behavioral disorders
Patient with history of dizziness or motion sickness preventing virtual reality headset use
Patient with visual or hearing impairments preventing virtual reality headset use
Patient deprived of liberty, under guardianship, or curatorship
Patient not affiliated with a social security scheme
Pregnant or breastfeeding women
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for inclusion and consent
Treatment
Duration - Up to 7 to 8 months depending on follow-up schedule
Participants receive intramuscular injections of Cabotegravir and Rilpivirine at different injection sites and with or without a virtual reality headset according to randomization. Pain is assessed immediately after injections and daily for 7 days using a patient log.
5 visits including initial injection day and follow-ups at month 1, 2, 3, 4, 5, or 6 depending on patient status
End of Study Assessment
Duration - 1 day
Participants complete final assessments including pain evaluation, collection of adverse events, and questionnaires on procedure satisfaction and preferences.
1 visit (in-person)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
PREVENTION
Number of Arms
24
Similar Trials
Phase 2a Trial Evaluating Safety and Immune Response of MTBVAC Compared to BCG in Adolescents and Adults With and Without HIV
Comparing Pain from Cabotegravir and Rilpivirine Injections in Adults with HIV-1
Testing Injection Site and Virtual Reality Headset Use
Evaluating Low Dose Nivolumab Infusion in Adults with HIV on Antiretroviral Therapy to Reduce the Latent HIV Reservoir
Evaluating Combined Treatment Strategies to Reduce HIV Reservoirs and Achieve Sustained Remission Without Antiretroviral Therapy
Use of Lenacapavir with Optimized Background Treatment for Adults with HIV-1 in France A Retrospective Observational Study
Phase II Trial of Adding Adalimumab to Standard Tuberculosis Meningitis Treatment in HIV-1 Infected Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effectiveness of virtual reality intervention on reducing the pain, anxiety and fear of needle-related procedures in paediatric patients: A systematic review and meta-analysis.
Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
Celia Jonsson-Oldenbüttel, Jade Ghosn, Marc van der Valk...
Ventrogluteal versus dorsogluteal site selection: A cross-sectional study of muscle and subcutaneous fat thicknesses and an algorithm incorporating demographic and anthropometric data to predict injection outcome.
Theresa A Larkin, Elfriede Ashcroft, Asmahan Elgellaie...